Novocure Ltd Ord Sh (NVCR)

$15.43 +0.38 (2.52%)
Market Cap 1.79B
Revenue (ttm) 655.35M
Net Income (ttm) -136.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.79%
Debt to Equity Ratio 0.71
Volume 3,294,000
Avg Vol 1,767,088
Day's Range N/A - N/A
Shares Out 115.82M
Stochastic %K 41%
Beta 0.93
Analysts Strong Sell
Price Target $26.00

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, p...

Industry: Medical Devices
Sector: Healthcare
Address:
Neuhofstrasse 21, Baar, Switzerland
NeuroRad
NeuroRad Jun. 29 at 12:25 AM
$NVCR what’s with the way above average volume on Friday?
1 · Reply
MarketExplorerr
MarketExplorerr Jun. 27 at 8:41 PM
$NVCR bouncing around $15.43 after the massive 20% hit from that failed TRIDENT trial. Everyone was hoping earlier therapy initiation would expand the market, but the data just didn't show the survival benefit. Pipeline story took a real dent, just watching if this level can form a floor.
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 27 at 2:47 AM
$NVCR TTFs extending life
1 · Reply
Tdorsey1776
Tdorsey1776 Jun. 26 at 2:11 PM
$NVCR Keep shorting...if you live in the past and think Panc is Lung 2.0
0 · Reply
BullEngine
BullEngine Jun. 25 at 5:28 PM
$NVCR is up ~11% but volume is below average, so it feels more like a momentum follow-through than real accumulation. The +76% spike is still being digested, and holding above $80 shows some stability. Key question is whether it can build acceptance above $100 or just fade into a consolidation range.
1 · Reply
MarketExplorerr
MarketExplorerr Jun. 25 at 5:24 PM
$NVCR feels like one of those names where sentiment runs ahead of execution. The story around GBM treatment is real, but in the tape it usually takes more than optimism to sustain a move. Right now it still trades like hope is doing most of the lifting, and that only works until supply shows up.
1 · Reply
BB_88_
BB_88_ Jun. 24 at 5:46 PM
$NVCR sorry needs to do up and down first before break through 15 - drop coming now
0 · Reply
BB_88_
BB_88_ Jun. 24 at 5:23 PM
$NVCR expecting big drop into close 🤫
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 24 at 4:34 PM
$NVCR Keep shorting
1 · Reply
Twister8
Twister8 Jun. 24 at 4:32 PM
$NVCR trident proving out that TTF is not the future, company failed to find a compatible kill shot.
0 · Reply
Latest News on NVCR
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Jun 18, 2026, 9:41 PM EDT - 10 days ago

Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

Novocure falls -17.0%

2026-06-18T16:08:06.000Z - 10 days ago

Novocure falls -17.0%

Novocure price target lowered to $46 from $48 at H.C. Wainwright

2026-06-18T15:00:12.000Z - 10 days ago

Novocure price target lowered to $46 from $48 at H.C. Wainwright

Novocure falls -18.2%

2026-06-18T14:08:26.000Z - 10 days ago

Novocure falls -18.2%

Novocure says Phase 3 TRIDENT trial did not meet primary endpoint

2026-06-18T11:13:52.000Z - 11 days ago

Novocure says Phase 3 TRIDENT trial did not meet primary endpoint

Novocure's cancer treatment fails to meet late-stage trial goal

Jun 18, 2026, 7:08 AM EDT - 11 days ago

Novocure's cancer treatment fails to meet late-stage trial goal

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

Jun 18, 2026, 7:00 AM EDT - 11 days ago

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

NovoCure Proxy statement: Proxy filing

May 21, 2026, 8:00 AM EDT - 5 weeks ago

NovoCure Proxy statement: Proxy filing

Novocure price target raised to $17 from $13.50 at Wells Fargo

2026-05-04T10:36:48.000Z - 2 months ago

Novocure price target raised to $17 from $13.50 at Wells Fargo

Novocure price target raised to $20 from $16 at Evercore ISI

2026-05-01T12:15:56.000Z - 2 months ago

Novocure price target raised to $20 from $16 at Evercore ISI

Novocure reports Q1 EPS (62c), consensus (51c)

2026-04-30T13:13:37.000Z - 2 months ago

Novocure reports Q1 EPS (62c), consensus (51c)

Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M

2026-04-30T13:12:44.000Z - 2 months ago

Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M

NovoCure Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

NovoCure Earnings Call Transcript: Q1 2026

NovoCure Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

NovoCure Quarterly report: Q1 2026

NovoCure Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

NovoCure Earnings release: Q1 2026

NovoCure Slides: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

NovoCure Slides: Q1 2026

Novocure Reports First Quarter 2026 Financial Results

Apr 30, 2026, 7:00 AM EDT - 2 months ago

Novocure Reports First Quarter 2026 Financial Results

NovoCure Slides: Corporate presentation

Apr 29, 2026, 7:00 AM EDT - 2 months ago

NovoCure Slides: Corporate presentation

NovoCure Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

NovoCure Proxy statement: Proxy filing

NovoCure Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

NovoCure Proxy statement: Proxy filing

Novocure price target lowered to $16 from $23 at Evercore ISI

2026-04-06T12:12:23.000Z - 2 months ago

Novocure price target lowered to $16 from $23 at Evercore ISI

Novocure to Report First Quarter 2026 Financial Results

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Novocure to Report First Quarter 2026 Financial Results

Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

2026-03-26T11:11:40.000Z - 3 months ago

Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Mar 26, 2026, 7:00 AM EDT - 3 months ago

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

NovoCure Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 3 months ago

NovoCure Transcript: Leerink Global Healthcare Conference 2026

Novocure gets reimbursement approval in Japan for Optune Lua

2026-03-02T12:33:53.000Z - 4 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

Novocure gets reimbursement approval in Japan for Optune Lua

2026-03-02T12:30:14.000Z - 4 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Mar 2, 2026, 7:00 AM EST - 4 months ago

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure to Participate in 2026 Leerink Global Healthcare Conference

Feb 27, 2026, 4:30 PM EST - 4 months ago

Novocure to Participate in 2026 Leerink Global Healthcare Conference

NovoCure Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

NovoCure Earnings Call Transcript: Q4 2025

NovoCure Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

NovoCure Annual report: Q4 2025

NovoCure Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

NovoCure Earnings release: Q4 2025

NovoCure Slides: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

NovoCure Slides: Q4 2025

Novocure reports Q4 EPS (22c), consensus (41c)

2026-02-26T12:36:11.000Z - 4 months ago

Novocure reports Q4 EPS (22c), consensus (41c)

Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

2026-02-26T12:35:04.000Z - 4 months ago

Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Feb 26, 2026, 7:00 AM EST - 4 months ago

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Novocure says CMS rescinds revocation of billing privileges

2026-02-25T14:00:43.000Z - 4 months ago

Novocure says CMS rescinds revocation of billing privileges

Novocure jumps 11% after CMS reinstates Medicare billing privileges

2026-02-25T13:59:52.000Z - 4 months ago

Novocure jumps 11% after CMS reinstates Medicare billing privileges

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

Feb 24, 2026, 7:00 AM EST - 4 months ago

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Feb 12, 2026, 6:53 AM EST - 4 months ago

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

What's Happening With NovoCure Stock?

Feb 12, 2026, 6:15 AM EST - 4 months ago

What's Happening With NovoCure Stock?

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

Feb 11, 2026, 6:33 PM EST - 4 months ago

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Feb 11, 2026, 5:54 PM EST - 4 months ago

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 5 months ago

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

NovoCure Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 5 months ago

NovoCure Slides: Corporate presentation

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Jan 12, 2026, 7:00 AM EST - 5 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 7:00 AM EST - 6 months ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 7 months ago

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Dec 1, 2025, 7:00 AM EST - 7 months ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 7 months ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:00 AM EST - 7 months ago

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Nov 12, 2025, 7:00 AM EST - 8 months ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

NovoCure Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 8 months ago

NovoCure Earnings Call Transcript: Q3 2025

NovoCure Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 8 months ago

NovoCure Quarterly report: Q3 2025

NovoCure Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 8 months ago

NovoCure Earnings release: Q3 2025

NovoCure Slides: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 8 months ago

NovoCure Slides: Q3 2025

Novocure Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 7:00 AM EDT - 8 months ago

Novocure Reports Third Quarter 2025 Financial Results

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 15, 2025, 7:00 AM EDT - 9 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure to Report Third Quarter 2025 Financial Results

Oct 1, 2025, 7:00 AM EDT - 9 months ago

Novocure to Report Third Quarter 2025 Financial Results

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 29, 2025, 4:30 PM EDT - 9 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 15, 2025, 7:00 AM EDT - 10 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 3:20 PM EDT - 10 months ago

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 2:00 PM EDT - 10 months ago

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 9:30 AM EDT - 10 months ago

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Novocure Announces Upcoming Investor Events

Aug 28, 2025, 7:00 AM EDT - 10 months ago

Novocure Announces Upcoming Investor Events

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 25, 2025, 7:00 AM EDT - 11 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Aug 20, 2025, 7:00 AM EDT - 11 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

NovoCure Earnings Call Transcript: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q2 2025

NovoCure Earnings release: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings release: Q2 2025

NovoCure Quarterly report: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Quarterly report: Q2 2025

NovoCure Slides: Q2 2025

Jul 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Slides: Q2 2025

Novocure Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Novocure to Report Second Quarter 2025 Financial Results

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report Second Quarter 2025 Financial Results

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 12:50 PM EDT - 1 year ago

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

NovoCure Slides: Corporate Presentation

Jun 3, 2025, 7:00 AM EDT - 1 year ago

NovoCure Slides: Corporate Presentation

NovoCure Transcript: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Transcript: Study Result

NovoCure Press release: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Press release: Study Result

NovoCure Slides: Study Result

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Slides: Study Result

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 3:08 PM EDT - 1 year ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025, 8:00 AM EDT - 1 year ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

NovoCure Earnings Call Transcript: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q1 2025

NovoCure Earnings release: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings release: Q1 2025

NovoCure Quarterly report: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Quarterly report: Q1 2025

NovoCure Slides: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Slides: Q1 2025

Novocure Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 1 year ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 22, 2025, 7:09 AM EDT - 1 year ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

NovoCure Proxy statement: Proxy Filing

NovoCure Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

NovoCure Proxy statement: Proxy Filing

Novocure to Report First Quarter 2025 Financial Results

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2025 Financial Results

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 4:20 PM EDT - 1 year ago

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NovoCure Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings Call Transcript: Q4 2024

NovoCure Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings release: Q4 2024

NovoCure Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Annual report: Q4 2024

NovoCure Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Slides: Q4 2024

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 22, 2025, 4:00 AM EST - 1 year ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:00 PM EST - 1 year ago

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 13, 2025, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:17 AM EST - 1 year ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:02 AM EST - 1 year ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Dec 2, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

NovoCure Earnings Call Transcript: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q3 2024

NovoCure Earnings release: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings release: Q3 2024

NovoCure Quarterly report: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Quarterly report: Q3 2024

NovoCure Slides: Q3 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Slides: Q3 2024

NovoCure Slides: Corporate Presentation

Oct 30, 2024, 7:30 AM EDT - 1 year ago

NovoCure Slides: Corporate Presentation

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:02 AM EDT - 1 year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

NeuroRad
NeuroRad Jun. 29 at 12:25 AM
$NVCR what’s with the way above average volume on Friday?
1 · Reply
MarketExplorerr
MarketExplorerr Jun. 27 at 8:41 PM
$NVCR bouncing around $15.43 after the massive 20% hit from that failed TRIDENT trial. Everyone was hoping earlier therapy initiation would expand the market, but the data just didn't show the survival benefit. Pipeline story took a real dent, just watching if this level can form a floor.
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 27 at 2:47 AM
$NVCR TTFs extending life
1 · Reply
Tdorsey1776
Tdorsey1776 Jun. 26 at 2:11 PM
$NVCR Keep shorting...if you live in the past and think Panc is Lung 2.0
0 · Reply
BullEngine
BullEngine Jun. 25 at 5:28 PM
$NVCR is up ~11% but volume is below average, so it feels more like a momentum follow-through than real accumulation. The +76% spike is still being digested, and holding above $80 shows some stability. Key question is whether it can build acceptance above $100 or just fade into a consolidation range.
1 · Reply
MarketExplorerr
MarketExplorerr Jun. 25 at 5:24 PM
$NVCR feels like one of those names where sentiment runs ahead of execution. The story around GBM treatment is real, but in the tape it usually takes more than optimism to sustain a move. Right now it still trades like hope is doing most of the lifting, and that only works until supply shows up.
1 · Reply
BB_88_
BB_88_ Jun. 24 at 5:46 PM
$NVCR sorry needs to do up and down first before break through 15 - drop coming now
0 · Reply
BB_88_
BB_88_ Jun. 24 at 5:23 PM
$NVCR expecting big drop into close 🤫
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 24 at 4:34 PM
$NVCR Keep shorting
1 · Reply
Twister8
Twister8 Jun. 24 at 4:32 PM
$NVCR trident proving out that TTF is not the future, company failed to find a compatible kill shot.
0 · Reply
BB_88_
BB_88_ Jun. 24 at 4:19 PM
$NVCR short 14.9 day trade only
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 24 at 1:41 PM
$NVCR You guys should keep adding to your short position all the way thru the next Panc ramp readout.
0 · Reply
Winorbust
Winorbust Jun. 23 at 8:16 PM
$DFNS $NEXR $NVCR $PPBT Jascar lost sooooo much money on PPBT it would be hilarious if it wasn’t so bad. But don’t forget Jascar also ignored and even blocked anyone who disagreed with him or tried warning him
0 · Reply
Stonkapedia
Stonkapedia Jun. 23 at 8:05 PM
$NVCR when this absolute turd rises to the top of my watchlist, you know it was an apocalyptic day on Wall Street
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 23 at 7:48 PM
$NEXR scams pay off once in awhile right @jascar ? Eh maybe not on $PPBT but mayne $NVCR or $DFNS will end up being “real” 🧠
0 · Reply
Tdorsey1776
Tdorsey1776 Jun. 23 at 1:47 PM
$NVCR Trident should garner a yawn, not a sell IMO. Understand the next 12-18 months of catalysts with Panc ramp priority #1 and then Mets.
2 · Reply
JuggernautRaider
JuggernautRaider Jun. 23 at 1:27 PM
$RDHL israeli scsm just like $NVCR $NEXR and others 🤫
1 · Reply
DrBig
DrBig Jun. 23 at 3:13 AM
$NVCR this has been a tough hold. Tough to watch the slow climb then the sharp fall over and over.
0 · Reply
BB_88_
BB_88_ Jun. 22 at 5:27 PM
$NVCR in here 1k shares
1 · Reply
Tdorsey1776
Tdorsey1776 Jun. 22 at 3:36 PM
$NVCR Panc ramp will determine if the stock is cheap here.
2 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Jun. 21 at 8:30 PM
$NVCR while the ST board can debate the negative opinions on Trident trial, some more worthwhile weekend reading from KOLs and practicing docs at the Mayo clinic: https://www.mayoclinic.org/medical-professionals/cancer/news/2-major-advances-fuel-new-optimism-in-pancreatic-cancer-care/mac-20602539 "Mayo Clinic in Florida is currently prescribing TTFields in clinic."
1 · Reply
flychicken1991
flychicken1991 Jun. 20 at 8:25 PM
$NVCR Negative: this healthcare catalyst can pressure expectations for NVCR. Key news: NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss. Full catalyst map + source details on NewsImpact: https://clawpool.hihired.org/newsimpact/ticker/NVCR?utm_source=stocktwits&utm_medium=parent_url Not financial advice.
0 · Reply